Literature DB >> 7673236

Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity.

V Jullien-Flores1, O Dorseuil, F Romero, F Letourneur, S Saragosti, R Berger, A Tavitian, G Gacon, J H Camonis.   

Abstract

Ra1A and Ra1B are GTPases of unknown function and are activated by proteins, Ra1GDS, that interact with the active form of another GTPase, Ras. To elucidate Ral function, we have searched for proteins interacting with an activated form of Ra1A using the two-hybrid method and a Jurkat cell library. We have identified a partial cDNA encoding a protein, RLIP1, which binds to activated Ra1A and this binding requires an intact effector domain of Ra1A. Biochemical data with purified Ra1A confirm the genetic results. This protein also bears a region of homology with GTPase-activating protein (GAP) domains that are involved in the regulation of GTPases of the Rho family and, indeed, RLIP1 displays a GAP activity acting upon Rac1 and CDC42, but not RhoA. This GAP region is not required for RLIP1 binding to Ra1. The whole cDNA was cloned, and it encodes a 76-kDa polypeptide, RLIP76, which also binds RalA. The Rho pathway is involved in membrane and cytoskeleton modifications after mitogenic stimulation and acts in parallel to and synergistically with the Ras pathway. We propose that these pathways are linked through a cascade composed of Ras --> Ra1GDS --> Ra1 --> RLIP76 --> CDC42/Rac1/Rho, allowing modulation of the Rho pathway by the Ras pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673236     DOI: 10.1074/jbc.270.38.22473

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  119 in total

1.  Regulation of Ras signaling specificity by protein kinase C.

Authors:  G Rusanescu; T Gotoh; X Tian; L A Feig
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  Translation termination in eukaryotes: polypeptide release factor eRF1 is composed of functionally and structurally distinct domains.

Authors:  L Y Frolova; T I Merkulova; L L Kisselev
Journal:  RNA       Date:  2000-03       Impact factor: 4.942

3.  Ral-specific guanine nucleotide exchange factor activity opposes other Ras effectors in PC12 cells by inhibiting neurite outgrowth.

Authors:  T Goi; G Rusanescu; T Urano; L A Feig
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

4.  Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB.

Authors:  D O Henry; S A Moskalenko; K J Kaur; M Fu; R G Pestell; J H Camonis; M A White
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

5.  Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451.

Authors:  N D De Ruiter; B M Burgering; J L Bos
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

6.  RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells.

Authors:  Michail Shipitsin; Larry A Feig
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

7.  RalA activation at nascent lamellipodia of epidermal growth factor-stimulated Cos7 cells and migrating Madin-Darby canine kidney cells.

Authors:  Akiyuki Takaya; Yusuke Ohba; Kazuo Kurokawa; Michiyuki Matsuda
Journal:  Mol Biol Cell       Date:  2004-03-19       Impact factor: 4.138

Review 8.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

9.  Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis.

Authors:  Paola Margutti; Paola Matarrese; Fabrizio Conti; Tania Colasanti; Federica Delunardo; Antonella Capozzi; Tina Garofalo; Elisabetta Profumo; Rachele Riganò; Alessandra Siracusano; Cristiano Alessandri; Bruno Salvati; Guido Valesini; Walter Malorni; Maurizio Sorice; Elena Ortona
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

10.  Regression of prostate cancer xenografts by RLIP76 depletion.

Authors:  Sharad S Singhal; Cherice Roth; Kathryn Leake; Jyotsana Singhal; Sushma Yadav; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2008-11-25       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.